560 related articles for article (PubMed ID: 16618584)
1. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI.
van Lin EN; Fütterer JJ; Heijmink SW; van der Vight LP; Hoffmann AL; van Kollenburg P; Huisman HJ; Scheenen TW; Witjes JA; Leer JW; Barentsz JO; Visser AG
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):291-303. PubMed ID: 16618584
[TBL] [Abstract][Full Text] [Related]
2. Effect on therapeutic ratio of planning a boosted radiotherapy dose to the dominant intraprostatic tumour lesion within the prostate based on multifunctional MR parameters.
Riches SF; Payne GS; Desouza NM; Dearnaley D; Morgan VA; Morgan SC; Partridge M
Br J Radiol; 2014 May; 87(1037):20130813. PubMed ID: 24601648
[TBL] [Abstract][Full Text] [Related]
3. Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions.
Murray LJ; Lilley J; Thompson CM; Cosgrove V; Mason J; Sykes J; Franks K; Sebag-Montefiore D; Henry AM
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):406-15. PubMed ID: 24685447
[TBL] [Abstract][Full Text] [Related]
4. Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.
Kuang Y; Wu L; Hirata E; Miyazaki K; Sato M; Kwee SA
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):1017-25. PubMed ID: 25832692
[TBL] [Abstract][Full Text] [Related]
5. Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy.
Pickett B; Vigneault E; Kurhanewicz J; Verhey L; Roach M
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):921-9. PubMed ID: 10386651
[TBL] [Abstract][Full Text] [Related]
6. Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study.
Ost P; Speleers B; De Meerleer G; De Neve W; Fonteyne V; Villeirs G; De Gersem W
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):920-6. PubMed ID: 20675077
[TBL] [Abstract][Full Text] [Related]
7. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging.
Pouliot J; Kim Y; Lessard E; Hsu IC; Vigneron DB; Kurhanewicz J
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1196-207. PubMed ID: 15234056
[TBL] [Abstract][Full Text] [Related]
8. Dominant intraprostatic lesion boosting in sexual-sparing radiotherapy of prostate cancer: A planning feasibility study.
Ciabatti S; Ntreta M; Buwenge M; Gaudiano C; Sessagesimi E; Romani F; Angelini AL; Cammelli S; Macchia G; Deodato F; Zamagni A; Golfieri R; Morganti AG; Cilla S
Med Dosim; 2019 Winter; 44(4):356-364. PubMed ID: 30955990
[TBL] [Abstract][Full Text] [Related]
9. Dosimetric and radiobiological consequences of computed tomography-guided adaptive strategies for intensity modulated radiation therapy of the prostate.
Battista JJ; Johnson C; Turnbull D; Kempe J; Bzdusek K; Van Dyk J; Bauman G
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):874-80. PubMed ID: 23978708
[TBL] [Abstract][Full Text] [Related]
10. Intensity modulated radiation therapy dose painting for localized prostate cancer using ¹¹C-choline positron emission tomography scans.
Chang JH; Lim Joon D; Lee ST; Gong SJ; Anderson NJ; Scott AM; Davis ID; Clouston D; Bolton D; Hamilton CS; Khoo V
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e691-6. PubMed ID: 22658218
[TBL] [Abstract][Full Text] [Related]
11. Focal dose escalation for prostate cancer using
Zamboglou C; Thomann B; Koubar K; Bronsert P; Krauss T; Rischke HC; Sachpazidis I; Drendel V; Salman N; Reichel K; Jilg CA; Werner M; Meyer PT; Bock M; Baltas D; Grosu AL
Radiat Oncol; 2018 May; 13(1):81. PubMed ID: 29716617
[TBL] [Abstract][Full Text] [Related]
12. Sparing the penile bulb in the radical irradiation of clinically localised prostate carcinoma: A comparison between MRI and CT prostatic apex definition in 3DCRT, Linac-IMRT and Helical Tomotherapy.
Perna L; Fiorino C; Cozzarini C; Broggi S; Cattaneo GM; De Cobelli F; Mangili P; Di Muzio N; Calandrino R
Radiother Oncol; 2009 Oct; 93(1):57-63. PubMed ID: 19410316
[TBL] [Abstract][Full Text] [Related]
13. Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer.
Seppälä J; Seppänen M; Arponen E; Lindholm P; Minn H
Radiother Oncol; 2009 Nov; 93(2):234-40. PubMed ID: 19766336
[TBL] [Abstract][Full Text] [Related]
14. Multiparametric MRI-guided dose boost to dominant intraprostatic lesions in CT-based High-dose-rate prostate brachytherapy.
Wang T; Press RH; Giles M; Jani AB; Rossi P; Lei Y; Curran WJ; Patel P; Liu T; Yang X
Br J Radiol; 2019 May; 92(1097):20190089. PubMed ID: 30912959
[TBL] [Abstract][Full Text] [Related]
15. The feasibility of a dose painting procedure to treat prostate cancer based on mpMR images and hierarchical clustering.
Rezaeijo SM; Hashemi B; Mofid B; Bakhshandeh M; Mahdavi A; Hashemi MS
Radiat Oncol; 2021 Sep; 16(1):182. PubMed ID: 34544468
[TBL] [Abstract][Full Text] [Related]
16. Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy.
Nutting CM; Corbishley CM; Sanchez-Nieto B; Cosgrove VP; Webb S; Dearnaley DP
Br J Radiol; 2002 Feb; 75(890):151-61. PubMed ID: 11893639
[TBL] [Abstract][Full Text] [Related]
17. A planning study of focal dose escalations to multiparametric MRI-defined dominant intraprostatic lesions in prostate proton radiation therapy.
Wang T; Zhou J; Tian S; Wang Y; Patel P; Jani AB; Langen KM; Curran WJ; Liu T; Yang X
Br J Radiol; 2020 Mar; 93(1107):20190845. PubMed ID: 31904261
[TBL] [Abstract][Full Text] [Related]
18. MRI-guided localization of the dominant intraprostatic lesion and dose analysis of volumetric modulated arc therapy planning for prostate cancer.
Tamihardja J; Zenk M; Flentje M
Strahlenther Onkol; 2019 Feb; 195(2):145-152. PubMed ID: 30209535
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer.
Chera BS; Vargas C; Morris CG; Louis D; Flampouri S; Yeung D; Duvvuri S; Li Z; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):994-1002. PubMed ID: 19619961
[TBL] [Abstract][Full Text] [Related]
20. MRI-based treatment planning for radiotherapy: dosimetric verification for prostate IMRT.
Chen L; Price RA; Wang L; Li J; Qin L; McNeeley S; Ma CM; Freedman GM; Pollack A
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):636-47. PubMed ID: 15380601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
